Search results
-
Publish or Protect? (Spanish version)
Shih, Willy; Chai, SenCase HBS-615S15Service and Operations ManagementShould they patent inventions coming out of their manufacturing process development work, should they keep them as trade secrets, or should they publish them so that they would go into the public domain and nobody else could patent them? They wish to preserve their freedom to practice, but they are very concerned about competitors' ability to benefit from LEGO Group's R&D investments or alternately interfere with its freedom to operate.Starting at €8.20
-
PerkinElmer - Developing Products in China for China
Sato, Vicki L.; Jaeker, Christoph; Reda, KareemCase HBS-612032-EService and Operations ManagementTo maximize their effectiveness, color cases should be printed in color. Sym-Bio, an entrepreneurial Chinese diagnostic company with a product line in infectious disease testing, has agreed to be acquired by PerkinElmer, an international corporation with businesses in neonatal testing, life science services, and environmental health. Sym-Bio wants to accelerate its growth and competitive position in China through this strategic move, and PerkinEl...Starting at €8.20
-
The LEGO Group: Publish or Protect
Shih, Willy; Chai, SenCase HBS-613079-EService and Operations ManagementSenior managers at the LEGO Group are faced with a quandary: Should they patent inventions coming out of their manufacturing process development work, should they keep them as trade secrets, or should they publish them so that they would go into the public domain and nobody else could patent them? They wish to preserve their freedom to practice, but they are very concerned about competitors' ability to benefit from LEGO Group's R&D investments or...Starting at €8.20
-
BGI: Data-driven Research
Shih, Willy; Chai, SenCase HBS-614056-EService and Operations ManagementBGI has the largest installed gene-sequencing capacity in the world, and to Zhang Gengyun, general manager of the Life Sciences Division, this represented an opportunity to apply his training as a plant breeder and his early career work as a biochemist to improving important parts of the world food supply. But his biggest challenge was in scaling up his organization to address the multitude of opportunities he wanted to address. Along with its ma...Starting at €8.20
-
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
Sato, Vicki L.; Shih, Willy; Higgins, MattCase HBS-617022-EService and Operations ManagementThe leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are discussed.Starting at €5.74
-
Adnexus Therapeutics, Inc.: Considering the Exit
Sato, Vicki L.; Gordon, RachelCase HBS-609015-EService and Operations ManagementDr. John Mendlein, CEO of Adnexus Therapeutics Inc., (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month collaboration or continue with Adnexus' planned IPO.Starting at €8.20
-
Novozymes: Establishing the Cellulosic Ethanol Value Chain
Shih, Willy; Chai, SenCase HBS-614001-EService and Operations ManagementTo maximize their effectiveness, color cases should be printed in color. As the world's largest producer of industrial enzymes, Novozymes had invested heavily for many years to bio-engineer enzymes that could break down cellulose into fermentable sugar. In 2010, the company had launched what it thought would become a breakthrough product for the conversion of crop residues from corn into fermentable sugars for the production of motor fuels. But t...Starting at €8.20